Investment
Features
FeesSafety
Academy
More
Pluang+

Telesat reports Q1 2026 revenue drop, invests $171M in Lightspeed LEO satellite program, expects service launch in early 2028

Company Fundamentals
05 May 2026
GlobeNewsWire
View Source
Bearish
pluang ai news

Telesat announced a 25% revenue decline to $87 million and a net loss of $151 million for Q1 2026, mainly due to lower GEO segment revenue and a goodwill impairment. The company invested $171 million in its Lightspeed Low Earth Orbit (LEO) satellite program, aiming to start global commercial service by Q1 2028. Despite revenue pressures, Telesat maintains its 2026 guidance for GEO revenue and adjusted EBITDA and secured a multi-year contract with Northwestel for rural broadband in Nunavut. The addition of Military Ka-band spectrum to Lightspeed enhances its appeal to government and defense sectors globally.

More News

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.

A new report reveals more than 180 companies are actively developing over 200 PD-1 and PD-L1 inhibitors, a class of immunotherapies that boost the immune system to fight cancer. These drugs target various cancers including lung, bladder, liver, and e...

Market News
Bullish
14 minutes ago
Eversource named to TIME's America's Best Companies for 2026 for employee and sustainability excellence

Eversource named to TIME's America's Best Companies for 2026 for employee and sustainability excellence

Eversource has been recognized on TIME's list of America's Best Companies for 2026, highlighting its strong commitment to employee satisfaction, operational excellence, and sustainability. The ranking is based on surveys of over 217,000 employees and...

Market News
Bullish
14 minutes ago
Head and neck squamous cell carcinoma market to grow at 10.5% CAGR by 2036 driven by new immunotherapies

Head and neck squamous cell carcinoma market to grow at 10.5% CAGR by 2036 driven by new immunotherapies

The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a compound annual growth rate (CAGR) of 10.5% from 2026 to 2036, fueled by rising cancer incidence and the introduction of novel immunotherapies and targeted treatments....

Market News
Bullish
14 minutes ago
Poolside launches Laguna S 2.1, a powerful 118B-parameter AI model for coding, running on a single desktop.

Poolside launches Laguna S 2.1, a powerful 118B-parameter AI model for coding, running on a single desktop.

Poolside has released Laguna S 2.1, a 118-billion-parameter open-weight AI model designed for agentic coding that matches or outperforms much larger models. It is compact enough to run on a single NVIDIA DGX Spark desktop and is available under an op...

Others
Bullish
14 minutes ago
Law firm probes Omeros over stock drop after EMA rejects drug approval

Law firm probes Omeros over stock drop after EMA rejects drug approval

Pomerantz LLP is investigating Omeros Corporation for potential securities fraud following a significant stock price drop. The decline occurred after the European Medicines Agency's Committee for Medicinal Products for Human Use issued a negative opi...

Market News
Bearish
18 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App